Answers are grounded in this paper and cite their sources.
BACKGROUND: Liver transplantation (LT) is associated with an increased risk of de novo malignancies (DNM). Everolimus (EVR) is an mTOR inhibitor with immunosuppressive and potentially antineoplastic properties. OBJECTIVE: To evaluate the association between EVR use and DNM incidence following LT. METHODS: Emulated target trials were conducted using French nationwide administrative health records. The cloning-censoring-weighting approach was applied to estimate the effects of EVR initiation, EVR discontinuation, and concomitant tacrolimus use among EVR users. The primary outcome was the cumulative incidence of DNM. Secondary outcomes included survival and site-specific cancer incidence. RESULTS: A total of 7,981 patients underwent LT for cirrhosis or hepatocellular carcinoma (44%) between 2009 and 2020. The 10-year cumulative incidence of DNM was 25.7%. DNM were less frequent among patients who initiated EVR during the first three years after LT (HR= 0.84; 95% CI: 0.79-0.88). The discontinuation of EVR was associated with an increased risk of DNM (HR: 1.34; 95% CI: 1.21-1.45), whereas concomitant tacrolimus use was not significantly associated with DNM risk (HR: 1.03 [95% CI: 0.83-1.21]). Site-specific ETTs revealed a lower incidence of bladder, hematological, lung, prostate, skin, and lymphoma cancers with EVR use. The main results remained robust during the sensitivity analyses that used alternative definitions of lag times and grace periods. CONCLUSION: Sustained everolimus exposure was associated with a lower incidence of de novo malignancies after LT. These findings support everolimus-based immunosuppressive strategies incorporating calcineurin inhibitor minimization to potentially reduce the long-term oncologic risk. KEY OBJECTIVE: To evaluate the potential protective effect of everolimus in reducing the risk of de novo malignancies after liver transplantation. KNOWLEDGE GENERATED: In a series of nationwide population-based emulated target trials, the initiation of everolimus was associated with a significantly lower incidence of de novo malignancies (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.79-0.88). Conversely, the discontinuation of everolimus therapy was associated with a significantly increased risk of developing de novo malignancies (HR: 1.34; 95% CI: 1.21-1.45). IMPACT AND IMPLICATIONS: This study addressed the lack of randomized evidence regarding the role of everolimus (EVR) in preventing de novo malignancies after liver transplantation by leveraging a causal inference framework applied to nationwide data. These findings are important for transplant physicians, researchers, and policymakers, as they suggest that sustained EVR exposure is associated with a reduced risk of post-transplant malignancies without compromising overall survival. In practice, this supports the consideration of EVR as part of immunosuppressive strategies and highlights the potential risks associated with its discontinuation. These results may inform clinical decision-making and future research on optimizing long-term immunosuppression to balance graft protection and cancer risk.
No takes yet. Share an insight, caveat, or question.
Kounis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: